期刊
IMMUNITY
卷 43, 期 5, 页码 959-973出版社
CELL PRESS
DOI: 10.1016/j.immuni.2015.10.014
关键词
-
类别
资金
- International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Consortium (NAC) [SFP2120/2121]
- Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID) [UM1AI100663]
- Bill and Melinda Gates Foundation Collaboration
- American people through USAID
- James and Jessie Minor Chair in Immunology
Broadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV envelope (Env) trimer isolated from individual HIV-infected donors potently neutralize diverse HIV strains, but strategies for designing immunogens to elicit bnAbs have not been identified. Here, we compared four prototypes (PG9, CH01, PGT145, and CAP256.VRC26.09) of V2 apex bnAbs and showed that all recognized a core epitope of basic V2 residues and the glycan-N160. Two prototype bnAbs were derived from VH-germlines that were 99% identical and used a common germline D-gene encoded YYD-motif to interact with the V2-epitope. We identified isolates that were neutralized by inferred germline (iGL) versions of three of the prototype bnAbs. Soluble Env derived from one of these isolates was shown to form a well-ordered Env trimer that could serve as an immunogen to initiate a V2-apex bnAb response. These studies illustrate a strategy to transition from panels of bnAbs to vaccine candidates.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据